KLINIČKO-PATOLOŠKE KARAKTERISTIKE HORMONSKI NEZAVISNIH LOBULARNIH KARCINOMA DOJKE
Sažetak
Estrogen igra ulogu u proliferaciji luminalnog sloja epitelnih ćelija dojke i u razvoju karcinoma dojke. Oko 70% humanih karcinoma dojke pokazuje ekspresiju estrogenskih receptora. Na osnovu ekspresije hormonskih receptora, ovi karcinomi mogu se podeliti na hormonski zavisne i hormonski nezavisne. S obzirom na to da su podaci u svetskoj literaturi parcijalni, kao cilj ovog istraživanja postavljena je uporedna analiza ovih karakteristika hormonski zavisni i hormonski nezavisnih lobularnih karcinoma dojke. Analizirano je 138 slučajeva lobularnih karcinoma dojke u odnosu na njihov hormonski status. Dobijeni patohistološki, imunohistohemijski i klinički podaci upoređeni su studentovim t-testom i Fisherovim testom. Statistički značajne razlike između grupa bolesnica sa hormonski zavisnim i hormonski nezavisnim lobularnim karcinomom dojke pronađena je za starost bolesnica (p = 0,036) i nuklearni gradus (p = 0,006). Dok, sa druge strane, ne postoji statistička razlika između dve ispitivane grupe bolesnica u pogledu prisustva metastaza u aksilarnim limfnim čvorovima (p > 0,05). Nađeno je to da su bolesnice sa hormonski nezavisnim lobularnim karcinomima značajno starije od bolesnica sa hormonski zavisnim lobularnim karcinomom dojke, kao i da ekspresija hormonskih receptorane igra ključnu ulogu u metastaziranju ovog karcinoma u aksilarne limfne čvorove.
Reference
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Pro-gesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020;144:545-63. [CrossRef] [PubMed]
Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and manage-ment strategies. Int J Womens Health 2012;4:511-20. [CrossRef] [PubMed]
Douglas-Jones AG, Collett N, Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001;54:951-5. [CrossRef] [PubMed]
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C et al. Relationship between quantitative estrogen and progesterone receptor expression and human epider-mal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-65. [CrossRef] [PubMed]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomised trials. Lancet 2005;365:1687-717. [CrossRef] [PubMed]
Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67. [CrossRef] [PubMed]
Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41. [CrossRef] [PubMed]
Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6. [CrossRef] [PubMed]
Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of defferentiation as indi-cators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87. [CrossRef] [PubMed]
Frost AR, Terahata S, Siegel RS, Overmoyer B, Silverberg SG. An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol 1995;8:830-6. [PubMed]
Hammond MEH, Hayes DF, Dowsett M, Allred DJ, Hagerty KL, Badve S, et al. American society of clinical oncology/ college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:E1-E25. [CrossRef] [PubMed]
Lacroix M, Leclercq G. About GATA3, HNF #A and XBP, three genes co-expressed with estrogen alpha gene (ESR1) in breast cancer. Moll Cell Endocrinol 2004;219:1-7. [CrossRef] [PubMed]
Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997;45:1559-65. [CrossRef] [PubMed]
Muggia F. Hormonal management in breast cancer. Br Med J 1969;3(5663):179. [CrossRef] [PubMed]
Porter JC. Hormonal regulation of breast development and activity. J Invest Dermatol 1974;63:85-92. [CrossRef] [PubMed]